Financial Modeling Prep·2026-03-10 03:00Core Insights - LifeMD, Inc. reported a GAAP net loss of $0.04 per share for Q4 2025, which was better than the expected loss of $0.07, while revenue reached $46.9 million, a 4% year-over-year increase but slightly below analyst estimates [2][5] Financial Performance - For the full year 2025, LifeMD's revenue grew by 25% to $194.1 million, and adjusted EBITDA surged by 309% to $15.3 million [3] - In Q4 2025, adjusted EBITDA increased by 348% to $4.8 million, indicating strong operational leverage [3] Product Launch and Growth - LifeMD launched oral Wegovy after the year-end, with over 80% of new weight management patients starting branded therapy, contributing to record patient sign-ups in Q1 2026 [4] - The company ended 2025 with $36.8 million in cash and no debt, positioning itself well for future growth investments [4] - LifeMD's benefits infrastructure is expected to cover approximately 220 million Americans by Q2 2026, with strong growth in its women's health offering [4]